Cubist Systematic Strategies LLC Has $4.90 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Cubist Systematic Strategies LLC boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 149,489 shares of the specialty pharmaceutical company’s stock after buying an additional 9,967 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Supernus Pharmaceuticals were worth $4,896,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Royal Bank of Canada grew its position in Supernus Pharmaceuticals by 68.1% in the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after purchasing an additional 4,729 shares during the last quarter. Armistice Capital LLC grew its position in Supernus Pharmaceuticals by 7.4% in the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock worth $170,169,000 after purchasing an additional 360,000 shares during the last quarter. Ashford Capital Management Inc. grew its position in Supernus Pharmaceuticals by 3.8% in the 1st quarter. Ashford Capital Management Inc. now owns 566,556 shares of the specialty pharmaceutical company’s stock worth $18,555,000 after purchasing an additional 20,781 shares during the last quarter. Vident Advisory LLC grew its position in Supernus Pharmaceuticals by 3.4% in the 1st quarter. Vident Advisory LLC now owns 14,886 shares of the specialty pharmaceutical company’s stock worth $488,000 after purchasing an additional 494 shares during the last quarter. Finally, State of Wyoming grew its position in Supernus Pharmaceuticals by 58.8% in the 1st quarter. State of Wyoming now owns 4,754 shares of the specialty pharmaceutical company’s stock worth $156,000 after purchasing an additional 1,761 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have issued reports on SUPN. Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 6th. Piper Sandler raised their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a “neutral” rating in a research report on Friday, August 29th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $43.00.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CFO Timothy C. Dec sold 11,780 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $44.49, for a total value of $524,092.20. Following the transaction, the chief financial officer directly owned 1,246 shares in the company, valued at $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Frank Mottola sold 14,000 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.51, for a total transaction of $623,140.00. Following the completion of the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $689,726.96. This trade represents a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 179,606 shares of company stock worth $7,617,005 in the last 90 days. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $44.93 on Thursday. The firm’s 50-day simple moving average is $37.43 and its 200-day simple moving average is $34.06. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $45.94. The firm has a market cap of $2.52 billion, a P/E ratio of 39.07 and a beta of 0.79.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.